{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:22:21Z","timestamp":1793938941758,"version":"4.8.0"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1038\/s41571-020-0356-4","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T11:02:43Z","timestamp":1587380563000},"page":"475-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-9841","authenticated-orcid":false,"given":"Bruce R.","family":"Blazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"356_CR1","unstructured":"D\u2019Souza, A. & Fretham, C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides https:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/pages\/index.aspx (2019)."},{"key":"356_CR2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01.cji.0000165354.19171.8f","volume":"28","author":"A Lundqvist","year":"2005","unstructured":"Lundqvist, A. & Childs, R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J. Immunother. 28, 281\u2013288 (2005).","journal-title":"J. Immunother."},{"key":"356_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald, G. B. et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003\u20132007 versus 2013\u20132017 cohorts. Ann. Intern. Med. 172, 229\u2013239 (2020).","journal-title":"Ann. Intern. Med."},{"key":"356_CR4","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/bloodadvances.2019000614","volume":"3","author":"MA Meybodi","year":"2019","unstructured":"Meybodi, M. A. et al. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 3, 2581\u20132585 (2019).","journal-title":"Blood Adv."},{"key":"356_CR5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/s41409-019-0465-9","volume":"54","author":"JR Passweg","year":"2019","unstructured":"Passweg, J. R. et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transpl. 54, 1575\u20131585 (2019).","journal-title":"Bone Marrow Transpl."},{"key":"356_CR6","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","volume":"23","author":"Stem Cell Trialists\u2019 Collaborative Group.","year":"2005","unstructured":"Stem Cell Trialists\u2019 Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J. Clin. Oncol. 23, 5074\u20135087 (2005).","journal-title":"J. Clin. Oncol."},{"key":"356_CR7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI98888","volume":"129","author":"S Vuckovic","year":"2019","unstructured":"Vuckovic, S. et al. Bone marrow transplantation generates T cell-dependent control of myeloma in mice. J. Clin. Invest. 129, 106\u2013121 (2019).","journal-title":"J. Clin. Invest."},{"key":"356_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","volume":"4","author":"DJ Chung","year":"2016","unstructured":"Chung, D. J. et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol. Res. 4, 61\u201371 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"356_CR9","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood.V128.22.2102.2102","volume":"128","author":"M Yadav","year":"2016","unstructured":"Yadav, M. et al. Tigit, CD226 and PD-L1\/PD-1 are highly expressed by marrow-infiltrating T cells in patients with multiple myeloma. Blood 128, 2102\u20132102 (2016).","journal-title":"Blood"},{"key":"356_CR10","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","volume":"132","author":"SA Minnie","year":"2018","unstructured":"Minnie, S. A. et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood 132, 1675\u20131688 (2018).","journal-title":"Blood"},{"key":"356_CR11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrclinonc.2014.102","volume":"11","author":"SW Choi","year":"2014","unstructured":"Choi, S. W. & Reddy, P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat. Rev. Clin. Oncol. 11, 536 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"356_CR12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar, B. R., Murphy, W. J. & Abedi, M. Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 12, 443 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"356_CR13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2014-02-514745","volume":"124","author":"KA Markey","year":"2014","unstructured":"Markey, K. A., MacDonald, K. P. & Hill, G. R. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 124, 354\u2013362 (2014).","journal-title":"Blood"},{"key":"356_CR14","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1084\/jem.20140116","volume":"211","author":"A Mirsoian","year":"2014","unstructured":"Mirsoian, A. et al. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J. Exp. Med. 211, 2373\u20132383 (2014).","journal-title":"J. Exp. Med."},{"key":"356_CR15","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.2019.0463","volume":"321","author":"WJ Murphy","year":"2019","unstructured":"Murphy, W. J. & Longo, D. L. The surprisingly positive association between obesity and cancer immunotherapy efficacy. JAMA 321, 1247\u20131248 (2019).","journal-title":"JAMA"},{"key":"356_CR16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.aax3760","volume":"366","author":"CK Stein-Thoeringer","year":"2019","unstructured":"Stein-Thoeringer, C. K. et al. Lactose drives enterococcus expansion to promote graft-versus-host disease. Science 366, 1143\u20131149 (2019).","journal-title":"Science"},{"key":"356_CR17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","volume":"132","author":"EC Fink","year":"2018","unstructured":"Fink, E. C. et al. Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132, 1535\u20131544 (2018).","journal-title":"Blood"},{"key":"356_CR18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood-2017-07-791608","volume":"131","author":"RG Dossa","year":"2018","unstructured":"Dossa, R. G. et al. Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. Blood 131, 108\u2013120 (2018).","journal-title":"Blood"},{"key":"356_CR19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/icb.2010.124","volume":"89","author":"M Bleakley","year":"2011","unstructured":"Bleakley, M. & Riddell, S. R. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol. Cell Biol. 89, 396\u2013407 (2011).","journal-title":"Immunol. Cell Biol."},{"key":"356_CR20","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1073\/pnas.0530192100","volume":"100","author":"WA Marijt","year":"2003","unstructured":"Marijt, W. A. et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl Acad. Sci. USA 100, 2742\u20132747 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"356_CR21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.285.5426.412","volume":"285","author":"WD Shlomchik","year":"1999","unstructured":"Shlomchik, W. D. et al. Prevention of graft versus host disease by inactivation of host antigen presenting cells. Science 285, 412\u2013415 (1999).","journal-title":"Science"},{"key":"356_CR22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2014.01.032","volume":"20","author":"M Bleakley","year":"2014","unstructured":"Bleakley, M. et al. Engineering human peripheral blood stem cell grafts that are depleted of naive T cells and retain functional pathogen-specific memory T cells. Biol. Blood Marrow Transpl. 20, 705\u2013716 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"356_CR23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI17601","volume":"112","author":"BE Anderson","year":"2003","unstructured":"Anderson, B. E. et al. Memory CD4+ T cells do not induce graft-versus-host disease. J. Clin. Invest. 112, 101\u2013108 (2003).","journal-title":"J. Clin. Invest."},{"key":"356_CR24","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/blood-2010-02-266296","volume":"116","author":"KP MacDonald","year":"2010","unstructured":"MacDonald, K. P. et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116, 3955\u20133963 (2010).","journal-title":"Blood"},{"key":"356_CR25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nm.2597","volume":"18","author":"M Koyama","year":"2012","unstructured":"Koyama, M. et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat. Med. 18, 135\u2013142 (2012).","journal-title":"Nat. Med."},{"key":"356_CR26","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2007-11-125294","volume":"111","author":"C Matte-Martone","year":"2008","unstructured":"Matte-Martone, C., Liu, J., Jain, D., McNiff, J. & Shlomchik, W. D. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Blood 111, 3884\u20133892 (2008).","journal-title":"Blood"},{"key":"356_CR27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm1089","volume":"10","author":"CC Matte","year":"2004","unstructured":"Matte, C. C. et al. Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10, 987\u2013992 (2004).","journal-title":"Nat. Med."},{"key":"356_CR28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/nm1309","volume":"11","author":"P Reddy","year":"2005","unstructured":"Reddy, P. et al. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat. Med. 11, 1244\u20131249 (2005).","journal-title":"Nat. Med."},{"key":"356_CR29","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2007-08-109678","volume":"111","author":"H Zheng","year":"2008","unstructured":"Zheng, H. et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 111, 2476\u20132484 (2008).","journal-title":"Blood"},{"key":"356_CR30","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1158\/1078-0432.CCR-17-2148","volume":"24","author":"KA Markey","year":"2018","unstructured":"Markey, K. A. et al. Flt-3L expansion of recipient CD8alpha+ dendritic cells deletes alloreactive donor T cells and represents an alternative to posttransplant cyclophosphamide for the prevention of GVHD. Clin. Cancer Res. 24, 1604\u20131616 (2018).","journal-title":"Clin. Cancer Res."},{"key":"356_CR31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1172\/JCI39165","volume":"120","author":"S Asakura","year":"2010","unstructured":"Asakura, S. et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J. Clin. Invest. 120, 2370\u20132378 (2010).","journal-title":"J. Clin. Invest."},{"key":"356_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2019.08.011","volume":"51","author":"M Koyama","year":"2019","unstructured":"Koyama, M. et al. MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota. Immunity 51, 1\u201314 (2019).","journal-title":"Immunity"},{"key":"356_CR33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20150329","volume":"212","author":"M Koyama","year":"2015","unstructured":"Koyama, M. et al. Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. J. Exp. Med. 212, 1303\u20131321 (2015).","journal-title":"J. Exp. Med."},{"key":"356_CR34","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1182\/bloodadvances.2019000053","volume":"3","author":"KH Gartlan","year":"2019","unstructured":"Gartlan, K. H. et al. Donor T-cell-derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract. Blood Adv. 3, 2859\u20132865 (2019).","journal-title":"Blood Adv."},{"key":"356_CR35","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher, M. J. et al. Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med. 379, 2330\u20132341 (2018).","journal-title":"N. Engl. J. Med."},{"key":"356_CR36","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","volume":"361","author":"L Vago","year":"2009","unstructured":"Vago, L. et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 361, 478\u2013488 (2009).","journal-title":"N. Engl. J. Med."},{"key":"356_CR37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"356_CR38","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1182\/blood.V93.10.3267.410k22_3267_3275","volume":"93","author":"DW Beelen","year":"1999","unstructured":"Beelen, D. W., Elmaagacli, A., Muller, K. D., Hirche, H. & Schaefer, U. W. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long term follow-up of an open-label prospective randomized trial. Blood 93, 3267\u20133275 (1999).","journal-title":"Blood"},{"key":"356_CR39","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1182\/blood.V80.10.2668.2668","volume":"80","author":"DW Beelen","year":"1992","unstructured":"Beelen, D. W. et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 80, 2668\u20132676 (1992).","journal-title":"Blood"},{"key":"356_CR40","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJM198302103080602","volume":"308","author":"R Storb","year":"1983","unstructured":"Storb, R. et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N. Engl. J. Med. 308, 302\u2013307 (1983).","journal-title":"N. Engl. J. Med."},{"key":"356_CR41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ni.3400","volume":"17","author":"ND Mathewson","year":"2016","unstructured":"Mathewson, N. D. et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat. Immunol. 17, 505\u2013513 (2016).","journal-title":"Nat. Immunol."},{"key":"356_CR42","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.bbmt.2016.01.010","volume":"22","author":"JU Peled","year":"2016","unstructured":"Peled, J. U. et al. Members of the intestinal microbiota are associated with relapse after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl. 22, S23\u2013S24 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"356_CR43","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","volume":"133","author":"R Zeiser","year":"2019","unstructured":"Zeiser, R. & Vago, L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood 133, 1290\u20131297 (2019).","journal-title":"Blood"},{"key":"356_CR44","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1172\/JCI85736","volume":"127","author":"C Matte-Martone","year":"2017","unstructured":"Matte-Martone, C. et al. Differential requirements for myeloid leukemia IFN-gamma conditioning determine graft-versus-leukemia resistance and sensitivity. J. Clin. Invest. 127, 2765\u20132776 (2017).","journal-title":"J. Clin. Invest."},{"key":"356_CR45","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter, R. B. et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 122, 1813\u20131821 (2013).","journal-title":"Blood"},{"key":"356_CR46","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie, S. A. & Hill, G. R. Immunotherapy of multiple myeloma. J. Clin. Invest. 130, 1565\u20131575 (2020).","journal-title":"J. Clin. Invest."},{"key":"356_CR47","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","volume":"78","author":"AM Marmont","year":"1991","unstructured":"Marmont, A. M. et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78, 2120\u20132130 (1991).","journal-title":"Blood"},{"key":"356_CR48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428199809057613","volume":"31","author":"U Brandenburg","year":"1998","unstructured":"Brandenburg, U., Gottlieb, D. & Bradstock, K. Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Leuk. Lymphoma 31, 545\u2013550 (1998).","journal-title":"Leuk. Lymphoma"},{"key":"356_CR49","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","volume":"86","author":"HJ Kolb","year":"1995","unstructured":"Kolb, H. J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86, 2041\u20132050 (1995).","journal-title":"Blood"},{"key":"356_CR50","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-019-0617-y","volume":"54","author":"RJ Soiffer","year":"2019","unstructured":"Soiffer, R. J. Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 54, 798\u2013802 (2019).","journal-title":"Bone Marrow Transpl."},{"key":"356_CR51","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/bloodadvances.2018019208","volume":"2","author":"LK Schoch","year":"2018","unstructured":"Schoch, L. K. et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv. 2, 2226\u20132229 (2018).","journal-title":"Blood Adv."},{"key":"356_CR52","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1182\/bloodadvances.2019000453","volume":"3","author":"AS Henden","year":"2019","unstructured":"Henden, A. S. et al. Pegylated interferon-2alpha invokes graft-versus-leukemia effects in patients relapsing after allogeneic stem cell transplantation. Blood Adv. 3, 3013\u20133019 (2019).","journal-title":"Blood Adv."},{"key":"356_CR53","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1172\/JCI75935","volume":"124","author":"KA Alexander","year":"2014","unstructured":"Alexander, K. A. et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J. Clin. Invest. 124, 4266\u20134280 (2014).","journal-title":"J. Clin. Invest."},{"key":"356_CR54","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1470-2045(14)71017-4","volume":"15","author":"GA Kennedy","year":"2014","unstructured":"Kennedy, G. A. et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial. Lancet Oncol. 15, 1451\u20131459 (2014).","journal-title":"Lancet Oncol."},{"key":"356_CR55","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","volume":"33","author":"K Nakamura","year":"2018","unstructured":"Nakamura, K. et al. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell 33, 634\u2013648 (2018).","journal-title":"Cancer Cell"},{"key":"356_CR56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127684","volume":"4","author":"AL Garfall","year":"2019","unstructured":"Garfall, A. L. et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 4, e127684 (2019).","journal-title":"JCI Insight"},{"key":"356_CR57","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont, M. J. et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 134, 1585\u20131597 (2019).","journal-title":"Blood"},{"key":"356_CR58","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"356_CR59","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"356_CR60","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","volume":"23","author":"A Ghosh","year":"2017","unstructured":"Ghosh, A. et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat. Med. 23, 242\u2013249 (2017).","journal-title":"Nat. Med."},{"key":"356_CR61","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011).","journal-title":"N. Engl. J. Med."},{"key":"356_CR62","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis, A. G. et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat. Med. 25, 1064\u20131072 (2019).","journal-title":"Nat. Med."},{"key":"356_CR63","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"356_CR64","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/leu.2016.254","volume":"31","author":"MH Qazilbash","year":"2017","unstructured":"Qazilbash, M. H. et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31, 697\u2013704 (2017).","journal-title":"Leukemia"},{"key":"356_CR65","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","volume":"132","author":"LP McLaughlin","year":"2018","unstructured":"McLaughlin, L. P. et al. EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132, 2351\u20132361 (2018).","journal-title":"Blood"},{"key":"356_CR66","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"E Doubrovina","year":"2012","unstructured":"Doubrovina, E. et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119, 2644\u20132656 (2012).","journal-title":"Blood"},{"key":"356_CR67","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser, R. et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29, 2062\u20132068 (2015).","journal-title":"Leukemia"},{"key":"356_CR68","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","volume":"122","author":"C Cutler","year":"2013","unstructured":"Cutler, C. et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 122, 1510\u20131517 (2013).","journal-title":"Blood"},{"key":"356_CR69","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","volume":"108","author":"C Cutler","year":"2006","unstructured":"Cutler, C. et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108, 756\u2013762 (2006).","journal-title":"Blood"},{"key":"356_CR70","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2010-03-271940","volume":"117","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood 117, 299\u2013308 (2011).","journal-title":"Blood"},{"key":"356_CR71","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood-2018-03-841155","volume":"132","author":"V Radojcic","year":"2018","unstructured":"Radojcic, V. et al. Notch signaling mediated by delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice. Blood 132, 2188\u20132200 (2018).","journal-title":"Blood"},{"key":"356_CR72","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew, N. R. et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat. Med. 24, 282 (2018).","journal-title":"Nat. Med."},{"key":"356_CR73","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","volume":"2","author":"SM Jaglowski","year":"2018","unstructured":"Jaglowski, S. M. & Blazar, B. R. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2, 2012\u20132019 (2018).","journal-title":"Blood Adv."},{"key":"356_CR74","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","volume":"124","author":"JA Dubovsky","year":"2014","unstructured":"Dubovsky, J. A. et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J. Clin. Invest. 124, 4867\u20134876 (2014).","journal-title":"J. Clin. Invest."},{"key":"356_CR75","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1182\/blood-2014-08-595470","volume":"125","author":"R Flynn","year":"2015","unstructured":"Flynn, R. et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood 125, 4085\u20134094 (2015).","journal-title":"Blood"},{"key":"356_CR76","first-page":"1677","volume":"124","author":"CC Pai","year":"2014","unstructured":"Pai, C. C. et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood 124, 1677\u20131688 (2014).","journal-title":"Blood"},{"key":"356_CR77","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2009-07-231092","volume":"114","author":"J Koreth","year":"2009","unstructured":"Koreth, J. et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 114, 3956\u20133959 (2009).","journal-title":"Blood"},{"key":"356_CR78","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","volume":"30","author":"J Koreth","year":"2012","unstructured":"Koreth, J. et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J. Clin. Oncol. 30, 3202\u20133208 (2012).","journal-title":"J. Clin. Oncol."},{"key":"356_CR79","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/ajt.15305","volume":"19","author":"K Paz","year":"2019","unstructured":"Paz, K. et al. Targeting PI3Kdelta function for amelioration of murine chronic graft-versus-host disease. Am. J. Transpl. 19, 1820\u20131830 (2019).","journal-title":"Am. J. Transpl."},{"key":"356_CR80","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1084\/jem.193.11.1311","volume":"193","author":"PA Taylor","year":"2001","unstructured":"Taylor, P. A., Noelle, R. J. & Blazar, B. R. CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 193, 1311\u20131318 (2001).","journal-title":"J. Exp. Med."},{"key":"356_CR81","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.V99.10.3493","volume":"99","author":"PA Taylor","year":"2002","unstructured":"Taylor, P. A., Lees, C. J. & Blazar, B. R. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493\u20133499 (2002).","journal-title":"Blood"},{"key":"356_CR82","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.20020399","volume":"196","author":"P Hoffmann","year":"2002","unstructured":"Hoffmann, P., Ermann, J., Edinger, M., Fathman, C. G. & Strober, S. Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196, 389\u2013399 (2002).","journal-title":"J. Exp. Med."},{"key":"356_CR83","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1084\/jem.20020090","volume":"196","author":"JL Cohen","year":"2002","unstructured":"Cohen, J. L., Trenado, A., Vasey, D., Klatzmann, D. & Salomon, B. L. CD4+CD25+ immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196, 401\u2013406 (2002).","journal-title":"J. Exp. Med."},{"key":"356_CR84","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","volume":"117","author":"CG Brunstein","year":"2011","unstructured":"Brunstein, C. G. et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117, 1061\u20131070 (2011).","journal-title":"Blood"},{"key":"356_CR85","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","volume":"127","author":"CG Brunstein","year":"2016","unstructured":"Brunstein, C. G. et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 127, 1044\u20131051 (2016).","journal-title":"Blood"},{"key":"356_CR86","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","volume":"9","author":"M Edinger","year":"2003","unstructured":"Edinger, M. et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9, 1144\u20131150 (2003).","journal-title":"Nat. Med."},{"key":"356_CR87","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI17702","volume":"112","author":"A Trenado","year":"2003","unstructured":"Trenado, A. et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. 112, 1688\u20131696 (2003).","journal-title":"J. Clin. Invest."},{"key":"356_CR88","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.bbmt.2017.07.009","volume":"23","author":"B Del Papa","year":"2017","unstructured":"Del Papa, B. et al. Clinical-grade-expanded regulatory T cells prevent graft-versus-host disease while allowing a powerful T cell-dependent graft-versus-leukemia effect in murine models. Biol. Blood Marrow Transpl. 23, 1847\u20131851 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"356_CR89","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/2326-6066.CIR-13-0049","volume":"1","author":"BD Choi","year":"2013","unstructured":"Choi, B. D. et al. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol. Res. 1, 163 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"356_CR90","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.immuni.2004.09.002","volume":"21","author":"WJ Grossman","year":"2004","unstructured":"Grossman, W. J. et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21, 589\u2013601 (2004).","journal-title":"Immunity"},{"key":"356_CR91","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","volume":"117","author":"M Di Ianni","year":"2011","unstructured":"Di Ianni, M. et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117, 3921\u20133928 (2011).","journal-title":"Blood"},{"key":"356_CR92","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2009-03-208181","volume":"114","author":"Q Zhou","year":"2009","unstructured":"Zhou, Q. et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 114, 3793\u20133802 (2009).","journal-title":"Blood"},{"key":"356_CR93","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","volume":"15","author":"MJ Szczepanski","year":"2009","unstructured":"Szczepanski, M. J. et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin. Cancer Res. 15, 3325\u20133332 (2009).","journal-title":"Clin. Cancer Res."},{"key":"356_CR94","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1158\/0008-5472.CAN-04-1987","volume":"64","author":"L Zou","year":"2004","unstructured":"Zou, L. et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12\/CXCR4 signals. Cancer Res. 64, 8451\u20138455 (2004).","journal-title":"Cancer Res."},{"key":"356_CR95","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","volume":"124","author":"MF Martelli","year":"2014","unstructured":"Martelli, M. F. et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 124, 638\u2013644 (2014).","journal-title":"Blood"},{"key":"356_CR96","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1182\/blood-2011-07-367987","volume":"119","author":"N Sawamukai","year":"2012","unstructured":"Sawamukai, N. et al. Cell-autonomous role of TGFbeta and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. Blood 119, 5575\u20135583 (2012).","journal-title":"Blood"},{"key":"356_CR97","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.4049\/jimmunol.1301181","volume":"191","author":"P Zhang","year":"2013","unstructured":"Zhang, P. et al. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. J. Immunol. 191, 5291\u20135303 (2013).","journal-title":"J. Immunol."},{"key":"356_CR98","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4049\/jimmunol.1200886","volume":"189","author":"AJ Beres","year":"2012","unstructured":"Beres, A. J. et al. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J. Immunol. 189, 464\u2013474 (2012).","journal-title":"J. Immunol."},{"key":"356_CR99","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbmt.2010.12.710","volume":"17","author":"K Semple","year":"2011","unstructured":"Semple, K., Yu, Y., Wang, D., Anasetti, C. & Yu, X. Z. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. Biol. Blood Marrow Transpl. 17, 309\u2013318 (2011).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"356_CR100","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4049\/jimmunol.1401250","volume":"195","author":"J Li","year":"2015","unstructured":"Li, J. et al. HY-specific induced regulatory T cells display high specificity and efficacy in the prevention of acute graft-versus-host disease. J. Immunol. 195, 717\u2013725 (2015).","journal-title":"J. Immunol."},{"key":"356_CR101","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/j.1600-6143.2011.03558.x","volume":"11","author":"KL Hippen","year":"2011","unstructured":"Hippen, K. L. et al. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am. J. Transpl. 11, 1148\u20131157 (2011).","journal-title":"Am. J. Transpl."},{"key":"356_CR102","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1146842","volume":"5","author":"J Heinrichs","year":"2016","unstructured":"Heinrichs, J. et al. CD8+ Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4+ Tregs in mice. Oncoimmunology 5, e1146842 (2016).","journal-title":"Oncoimmunology"},{"key":"356_CR103","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ni.1774","volume":"10","author":"X Zhou","year":"2009","unstructured":"Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000\u20131007 (2009).","journal-title":"Nat. Immunol."},{"key":"356_CR104","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1126\/science.1191996","volume":"329","author":"YP Rubtsov","year":"2010","unstructured":"Rubtsov, Y. P. et al. Stability of the regulatory T cell lineage in vivo. Science 329, 1667\u20131671 (2010).","journal-title":"Science"},{"key":"356_CR105","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/ni.2420","volume":"13","author":"W Fu","year":"2012","unstructured":"Fu, W. et al. A multiply redundant genetic switch \u2018locks in\u2019 the transcriptional signature of regulatory T cells. Nat. Immunol. 13, 972\u2013980 (2012).","journal-title":"Nat. Immunol."},{"key":"356_CR106","volume":"2","author":"P Zhang","year":"2017","unstructured":"Zhang, P. et al. Eomesodermin promotes the development of type 1 regulatory T (TR1) cells. Sci. Immunol. 2, eaah7152 (2017).","journal-title":"Sci. Immunol."},{"key":"356_CR107","doi-asserted-by":"crossref","first-page":"E3432","DOI":"10.1073\/pnas.1408780111","volume":"111","author":"L Lu","year":"2014","unstructured":"Lu, L. et al. Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc. Natl Acad. Sci. USA 111, E3432\u2013E3440 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"356_CR108","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1215-2","volume":"570","author":"M Di Pilato","year":"2019","unstructured":"Di Pilato, M. et al. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature 570, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"356_CR109","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1084\/jem.20070719","volume":"204","author":"MJ Benson","year":"2007","unstructured":"Benson, M. J., Pino-Lagos, K., Rosemblatt, M. & Noelle, R. J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J. Exp. Med. 204, 1765\u20131774 (2007).","journal-title":"J. Exp. Med."},{"key":"356_CR110","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1084\/jem.20070590","volume":"204","author":"JL Coombes","year":"2007","unstructured":"Coombes, J. L. et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757\u20131764 (2007).","journal-title":"J. Exp. Med."},{"key":"356_CR111","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.4049\/jimmunol.1000598","volume":"185","author":"X Zhou","year":"2010","unstructured":"Zhou, X. et al. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J. Immunol. 185, 2675\u20132679 (2010).","journal-title":"J. Immunol."},{"key":"356_CR112","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0002-9610(89)90120-7","volume":"158","author":"RA Khafif","year":"1989","unstructured":"Khafif, R. A., Gelbfish, G. A., Attie, J. N., Tepper, P. & Zingale, R. Thirty-year experience with 457 radical neck dissections in cancer of the mouth, pharynx, and larynx. Am. J. Surg. 158, 303\u2013307 (1989).","journal-title":"Am. J. Surg."},{"key":"356_CR113","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1084\/jem.20151438","volume":"213","author":"X Yue","year":"2016","unstructured":"Yue, X. et al. Control of Foxp3 stability through modulation of TET activity. J. Exp. Med. 213, 377\u2013397 (2016).","journal-title":"J. Exp. Med."},{"key":"356_CR114","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.4049\/jimmunol.1502352","volume":"196","author":"V Sasidharan Nair","year":"2016","unstructured":"Sasidharan Nair, V., Song, M. H. & Oh, K. I. Vitamin C facilitates demethylation of the Foxp3 enhancer in a Tet-dependent manner. J. Immunol. 196, 2119\u20132131 (2016).","journal-title":"J. Immunol."},{"key":"356_CR115","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/bloodadvances.2019000531","volume":"3","author":"S Iamsawat","year":"2019","unstructured":"Iamsawat, S. et al. Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse. Blood Adv. 3, 4187\u20134201 (2019).","journal-title":"Blood Adv."},{"key":"356_CR116","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2013-12-544106","volume":"124","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. The polycomb repressive complex 2 governs life and death of peripheral T cells. Blood 124, 737\u2013749 (2014).","journal-title":"Blood"},{"key":"356_CR117","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.immuni.2015.01.007","volume":"42","author":"M DuPage","year":"2015","unstructured":"DuPage, M. et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 42, 227\u2013238 (2015).","journal-title":"Immunity"},{"key":"356_CR118","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1073\/pnas.1712452115","volume":"115","author":"BC Betts","year":"2018","unstructured":"Betts, B. C. et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc. Natl Acad. Sci. USA 115, 1582\u20131587 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"356_CR119","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.ymthe.2017.06.029","volume":"25","author":"G Locafaro","year":"2017","unstructured":"Locafaro, G. et al. IL-10-engineered human CD4+ Tr1 cells eliminate myeloid leukemia in an HLA class I-dependent mechanism. Mol. Ther. 25, 2254\u20132269 (2017).","journal-title":"Mol. Ther."},{"key":"356_CR120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1084\/jem.134.1.83","volume":"134","author":"G Cudkowicz","year":"1971","unstructured":"Cudkowicz, G. & Bennett, M. Peculiar immunobiology of bone marrow allografts: I. Graft rejection by irradiated responder mice. J. Exp. Med. 134, 83\u2013102 (1971).","journal-title":"J. Exp. Med."},{"key":"356_CR121","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.134.6.1513","volume":"134","author":"G Cudkowicz","year":"1971","unstructured":"Cudkowicz, G. & Bennett, M. Peculiar immunobiology of bone marrow allografts: II. Rejection of parental grafts by resistant F1 hybrid mice. J. Exp. Med. 134, 1513\u20131528 (1971).","journal-title":"J. Exp. Med."},{"key":"356_CR122","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri.2015.9","volume":"16","author":"A Cerwenka","year":"2016","unstructured":"Cerwenka, A. & Lanier, L. L. Natural killer cell memory in infection, inflammation and cancer. Nat. Rev. Immunol. 16, 112 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"356_CR123","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","volume":"47","author":"AG Freud","year":"2017","unstructured":"Freud, A. G., Mundy-Bosse, B. L., Yu, J. & Caligiuri, M. A. The broad spectrum of human natural killer cell diversity. Immunity 47, 820\u2013833 (2017).","journal-title":"Immunity"},{"key":"356_CR124","doi-asserted-by":"crossref","first-page":"8795673","DOI":"10.1155\/2019\/8795673","volume":"2019","author":"C Capuano","year":"2019","unstructured":"Capuano, C. et al. Memory NK cell features exploitable in anticancer immunotherapy. J. Immunol. Res. 2019, 8795673 (2019).","journal-title":"J. Immunol. Res."},{"key":"356_CR125","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.it.2017.12.001","volume":"39","author":"JE Boudreau","year":"2018","unstructured":"Boudreau, J. E. & Hsu, K. C. Natural killer cell education and the response to infection and cancer therapy: stay tuned. Trends Immunol. 39, 222\u2013239 (2018).","journal-title":"Trends Immunol."},{"key":"356_CR126","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1172\/JCI129338","volume":"129","author":"JJ Hodgins","year":"2019","unstructured":"Hodgins, J. J., Khan, S. T., Park, M. M., Auer, R. C. & Ardolino, M. Killers 2.0: NK cell therapies at the forefront of cancer control. J. Clin. Invest. 129, 3499\u20133510 (2019).","journal-title":"J. Clin. Invest."},{"key":"356_CR127","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nature10624","volume":"481","author":"SN Waggoner","year":"2012","unstructured":"Waggoner, S. N., Cornberg, M., Selin, L. K. & Welsh, R. M. Natural killer cells act as rheostats modulating antiviral T cells. Nature 481, 394 (2012).","journal-title":"Nature"},{"key":"356_CR128","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI1268","volume":"101","author":"O Asai","year":"1998","unstructured":"Asai, O. et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J. Clin. Invest. 101, 1835\u20131842 (1998).","journal-title":"J. Clin. Invest."},{"key":"356_CR129","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","volume":"115","author":"JA Olson","year":"2010","unstructured":"Olson, J. A. et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 115, 4293\u20134301 (2010).","journal-title":"Blood"},{"key":"356_CR130","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097\u20132100 (2002).","journal-title":"Science"},{"key":"356_CR131","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","volume":"22","author":"DA Lee","year":"2016","unstructured":"Lee, D. A. et al. Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial. Biol. Blood Marrow Transpl. 22, 1290\u20131298 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"356_CR132","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","volume":"24","author":"AT Bj\u00f6rklund","year":"2018","unstructured":"Bj\u00f6rklund, A. T. et al. Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Clin. Cancer Res. 24, 1834\u20131844 (2018).","journal-title":"Clin. Cancer Res."},{"key":"356_CR133","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","volume":"125","author":"NN Shah","year":"2015","unstructured":"Shah, N. N. et al. Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell\u2013depleted stem cell transplantation. Blood 125, 784\u2013792 (2015).","journal-title":"Blood"},{"key":"356_CR134","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","volume":"118","author":"A Curti","year":"2011","unstructured":"Curti, A. et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118, 3273\u20133279 (2011).","journal-title":"Blood"},{"key":"356_CR135","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz, J. E. et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28, 955 (2010).","journal-title":"J. Clin. Oncol."},{"key":"356_CR136","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051\u20133057 (2005).","journal-title":"Blood"},{"key":"356_CR137","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","volume":"22","author":"BC Shaffer","year":"2016","unstructured":"Shaffer, B. C. et al. Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transpl. 22, 705\u2013709 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"356_CR138","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.4049\/jimmunol.1600769","volume":"197","author":"M-L Sentman","year":"2016","unstructured":"Sentman, M.-L. et al. Mechanisms of acute toxicity in NKG2D chimeric antigen receptor T cell-treated mice. J. Immunol. 197, 4674\u20134685 (2016).","journal-title":"J. Immunol."},{"key":"356_CR139","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2015-02-629006","volume":"125","author":"MA Karimi","year":"2015","unstructured":"Karimi, M. A. et al. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. Blood 125, 3655\u20133663 (2015).","journal-title":"Blood"},{"key":"356_CR140","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","volume":"367","author":"JM Venstrom","year":"2012","unstructured":"Venstrom, J. M. et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl. J. Med. 367, 805\u2013816 (2012).","journal-title":"N. Engl. J. Med."},{"key":"356_CR141","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/blood-2016-03-706317","volume":"128","author":"T Sekine","year":"2016","unstructured":"Sekine, T. et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128, 297\u2013312 (2016).","journal-title":"Blood"},{"key":"356_CR142","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2018-09-874990","volume":"133","author":"A Hallner","year":"2019","unstructured":"Hallner, A. et al. The HLA-B \u221221 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood 133, 1479\u20131488 (2019).","journal-title":"Blood"},{"key":"356_CR143","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.bbmt.2016.05.016","volume":"22","author":"V Bachanova","year":"2016","unstructured":"Bachanova, V. et al. Donor KIR B genotype improves progression-free survival of non-Hodgkin lymphoma patients receiving unrelated donor transplantation. Biol. Blood Marrow Transpl. 22, 1602\u20131607 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"356_CR144","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2014-03-565069","volume":"124","author":"L Oevermann","year":"2014","unstructured":"Oevermann, L. et al. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood 124, 2744\u20132747 (2014).","journal-title":"Blood"},{"key":"356_CR145","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731\u20131743.e13 (2018).","journal-title":"Cell"},{"key":"356_CR146","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.beha.2016.10.010","volume":"29","author":"BC Shaffer","year":"2016","unstructured":"Shaffer, B. C. & Hsu, K. C. How important is NK alloreactivity and KIR in allogeneic transplantation? Best Pract. Res. Clin. Haematol. 29, 351\u2013358 (2016).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"356_CR147","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.0001-2815.2004.00182.x","volume":"63","author":"A Bishara","year":"2004","unstructured":"Bishara, A. et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63, 204\u2013211 (2004).","journal-title":"Tissue Antigens"},{"key":"356_CR148","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-17-1767","volume":"24","author":"AK Erbe","year":"2018","unstructured":"Erbe, A. K. et al. Neuroblastoma patients\u2019 KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children\u2019s Oncology Group. Clin. Cancer Res. 24, 189\u2013196 (2018).","journal-title":"Clin. Cancer Res."},{"key":"356_CR149","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cell.2017.11.037","volume":"172","author":"AD Barrow","year":"2018","unstructured":"Barrow, A. D. et al. Natural killer cells control tumor growth by sensing a growth factor. Cell 172, 534\u2013548.e19 (2018).","journal-title":"Cell"},{"key":"356_CR150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-16-1743","volume":"23","author":"HC Tran","year":"2017","unstructured":"Tran, H. C. et al. TGF\u03b2R1 blockade with galunisertib (LY2157299) enhances anti-neuroblastoma activity of the anti-GD2 antibody dinutuximab (ch14.18) with natural killer cells. Clin. Cancer Res. 23, 804\u2013813 (2017).","journal-title":"Clin. Cancer Res."},{"key":"356_CR151","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.4049\/jimmunol.1500447","volume":"195","author":"E Ames","year":"2015","unstructured":"Ames, E. et al. NK cells preferentially target tumor cells with a cancer stem cell phenotype. J. Immunol. 195, 4010\u20134019 (2015).","journal-title":"J. Immunol."},{"key":"356_CR152","volume":"6","author":"R Tallerico","year":"2017","unstructured":"Tallerico, R. et al. NK cells control breast cancer and related cancer stem cell hematological spread. Oncoimmunology 6, e1284718 (2017).","journal-title":"Oncoimmunology"},{"key":"356_CR153","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla, A. M. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572, 254\u2013259 (2019).","journal-title":"Nature"},{"key":"356_CR154","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","volume":"119","author":"B Foley","year":"2012","unstructured":"Foley, B. et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119, 2665\u20132674 (2012).","journal-title":"Blood"},{"key":"356_CR155","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fimmu.2018.00389","volume":"9","author":"NH Litjens","year":"2018","unstructured":"Litjens, N. H., van der Wagen, L., Kuball, J. & Kwekkeboom, J. Potential beneficial effects of cytomegalovirus infection after transplantation. Front. Immunol. 9, 389 (2018).","journal-title":"Front. Immunol."},{"key":"356_CR156","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125553","volume":"4","author":"F Cichocki","year":"2019","unstructured":"Cichocki, F. et al. Adaptive NK cell reconstitution is associated with better clinical outcomes. JCI Insight 4, e125553 (2019).","journal-title":"JCI Insight"},{"key":"356_CR157","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127729","volume":"4","author":"M Alvarez","year":"2019","unstructured":"Alvarez, M. et al. Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. JCI Insight 4, e127729 (2019).","journal-title":"JCI Insight"},{"key":"356_CR158","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-1259","volume":"9","author":"W Dong","year":"2019","unstructured":"Dong, W. et al. The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov. 9, 1422\u20131437 (2019).","journal-title":"Cancer Discov."},{"key":"356_CR159","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","volume":"130","author":"SO Ciurea","year":"2017","unstructured":"Ciurea, S. O. et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood 130, 1857\u20131868 (2017).","journal-title":"Blood"},{"key":"356_CR160","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3389\/fimmu.2018.02041","volume":"9","author":"HS Kim","year":"2018","unstructured":"Kim, H. S. & Kim, N. Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells. Front. Immunol. 9, 2041 (2018).","journal-title":"Front. Immunol."},{"key":"356_CR161","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","volume":"130","author":"BM Haverkos","year":"2017","unstructured":"Haverkos, B. M. et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130, 221\u2013228 (2017).","journal-title":"Blood"},{"key":"356_CR162","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/2326-6066.CIR-18-0579","volume":"7","author":"T Pazina","year":"2019","unstructured":"Pazina, T. et al. Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma. Cancer Immunol. Res. 7, 1633\u20131646 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"356_CR163","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","volume":"123","author":"V Bachanova","year":"2014","unstructured":"Bachanova, V. et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123, 3855\u20133863 (2014).","journal-title":"Blood"},{"key":"356_CR164","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/bloodadvances.2017012369","volume":"2","author":"D Sarhan","year":"2018","unstructured":"Sarhan, D. et al. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. Blood Adv. 2, 1459\u20131469 (2018).","journal-title":"Blood Adv."},{"key":"356_CR165","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","volume":"3","author":"S Cooley","year":"2019","unstructured":"Cooley, S. et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 3, 1970\u20131980 (2019).","journal-title":"Blood Adv."},{"key":"356_CR166","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ccr.2012.09.009","volume":"22","author":"A Mishra","year":"2012","unstructured":"Mishra, A. et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 22, 645\u2013655 (2012).","journal-title":"Cancer Cell"},{"key":"356_CR167","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/blood.V97.10.3132","volume":"97","author":"CY Koh","year":"2001","unstructured":"Koh, C. Y. et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97, 3132\u20133137 (2001).","journal-title":"Blood"},{"key":"356_CR168","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-16-1108","volume":"22","author":"M Carlsten","year":"2016","unstructured":"Carlsten, M. et al. Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma. Clin. Cancer Res. 22, 5211\u20135222 (2016).","journal-title":"Clin. Cancer Res."},{"key":"356_CR169","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520 (2018).","journal-title":"Leukemia"},{"key":"356_CR170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li, Y., Hermanson, D. L., Moriarity, B. S. & Kaufman, D. S. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23, 181\u2013192.e5 (2018).","journal-title":"Cell Stem Cell"},{"key":"356_CR171","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","volume":"19","author":"M Boyiadzis","year":"2017","unstructured":"Boyiadzis, M. et al. Phase 1 clinical trial of adoptive immunotherapy using \u201coff-the-shelf\u201d activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy 19, 1225\u20131232 (2017).","journal-title":"Cytotherapy"},{"key":"356_CR172","volume":"5","author":"J Han","year":"2015","unstructured":"Han, J. et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep. 5, 11483 (2015).","journal-title":"Sci. Rep."},{"key":"356_CR173","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-019-0613-7","volume":"34","author":"C Quintarelli","year":"2019","unstructured":"Quintarelli, C. et al. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. Leukemia 34, 1102\u20131115 (2019).","journal-title":"Leukemia"},{"key":"356_CR174","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar, R. et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol. Res. 7, 363\u2013375 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"356_CR175","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-18-3183","volume":"25","author":"RA Burga","year":"2019","unstructured":"Burga, R. A. et al. Engineering the TGF\u03b2 receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma. Clin.Cancer Res. 25, 4400\u20134412 (2019).","journal-title":"Clin.Cancer Res."},{"key":"356_CR176","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"356_CR177","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","volume":"41","author":"C Wolschke","year":"2013","unstructured":"Wolschke, C. et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I\/II dose-finding study. Exp. Hematol. 41, 134\u2013142.e3 (2013).","journal-title":"Exp. Hematol."},{"key":"356_CR178","doi-asserted-by":"crossref","first-page":"24031","DOI":"10.18632\/oncotarget.15234","volume":"8","author":"M Giuliani","year":"2017","unstructured":"Giuliani, M., Janji, B. & Berchem, G. Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget 8, 24031 (2017).","journal-title":"Oncotarget"},{"key":"356_CR179","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2016-08-734020","volume":"129","author":"MD Bunting","year":"2017","unstructured":"Bunting, M. D. et al. GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. Blood 129, 630\u2013642 (2017).","journal-title":"Blood"},{"key":"356_CR180","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2016.391","volume":"31","author":"I Aldoss","year":"2017","unstructured":"Aldoss, I. et al. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors. Leukemia 31, 777\u2013787 (2017).","journal-title":"Leukemia"},{"key":"356_CR181","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","volume":"123","author":"MK Gleason","year":"2014","unstructured":"Gleason, M. K. et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123, 3016\u20133026 (2014).","journal-title":"Blood"},{"key":"356_CR182","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","volume":"19","author":"A Wiernik","year":"2013","unstructured":"Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 \u00d7 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844\u20133855 (2013).","journal-title":"Clin. Cancer Res."},{"key":"356_CR183","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1158\/2326-6066.CIR-16-0336","volume":"5","author":"JM Van den Bergh","year":"2017","unstructured":"Van den Bergh, J. M. et al. Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T-cell expansion. Cancer Immunol. Res. 5, 710\u2013715 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"356_CR184","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1080\/21645515.2016.1198455","volume":"12","author":"SS Tay","year":"2016","unstructured":"Tay, S. S., Carol, H. & Biro, M. TriKEs and BiKEs join CARs on the cancer immunotherapy highway. Hum. Vaccin. Immunother. 12, 2790\u20132796 (2016).","journal-title":"Hum. Vaccin. Immunother."},{"key":"356_CR185","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu, J. et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J. Clin. Invest. 128, 4654\u20134668 (2018).","journal-title":"J. Clin. Invest."},{"key":"356_CR186","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2016-11-752444","volume":"129","author":"J Du","year":"2017","unstructured":"Du, J. et al. Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129, 3121\u20133125 (2017).","journal-title":"Blood"},{"key":"356_CR187","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/sji.12289","volume":"81","author":"L Minculescu","year":"2015","unstructured":"Minculescu, L. & Sengel\u00f8v, H. The role of gamma delta T cells in haematopoietic stem cell transplantation. Scand. J. Immunol. 81, 459\u2013468 (2015).","journal-title":"Scand. J. Immunol."},{"key":"356_CR188","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","volume":"25","author":"X Xu","year":"2019","unstructured":"Xu, X. et al. NKT cells co-expressing a GD2-specific chimeric antigen receptor and IL-15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin.Cancer Res. 25, 7126\u20137138 (2019).","journal-title":"Clin.Cancer Res."},{"key":"356_CR189","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1172\/JCI25249","volume":"115","author":"ES Morris","year":"2005","unstructured":"Morris, E. S. et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J. Clin. Invest. 115, 3093\u20133103 (2005).","journal-title":"J. Clin. Invest."},{"key":"356_CR190","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/bloodadvances.2019000682","volume":"3","author":"LCM Arruda","year":"2019","unstructured":"Arruda, L. C. M., Gaballa, A. & Uhlin, M. Impact of gammadelta T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis. Blood Adv. 3, 3436\u20133448 (2019).","journal-title":"Blood Adv."},{"key":"356_CR191","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3389\/fimmu.2018.01062","volume":"9","author":"T Straetemans","year":"2018","unstructured":"Straetemans, T. et al. GMP-grade manufacturing of T cells engineered to express a defined gammadeltaTCR. Front. Immunol. 9, 1062 (2018).","journal-title":"Front. Immunol."},{"key":"356_CR192","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","volume":"39","author":"K Godder","year":"2007","unstructured":"Godder, K. et al. Long term disease-free survival in acute leukemia patients recovering with increased \u03b3\u03b4\u00a0T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transpl. 39, 751\u2013757 (2007).","journal-title":"Bone Marrow Transpl."},{"key":"356_CR193","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbmt.2014.09.027","volume":"21","author":"R Perko","year":"2015","unstructured":"Perko, R. et al. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia. Biol. Blood Marrow Transpl. 21, 130\u2013136 (2015).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"356_CR194","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3389\/fimmu.2019.01997","volume":"10","author":"L Minculescu","year":"2019","unstructured":"Minculescu, L. et al. Improved overall survival, relapse-free-survival and less graft-versus-host-disease in patients with high immune reconstitution of TCR gamma delta cells 2 months after allogeneic stem cell transplantation. Front. Immunol. 10, 1997 (2019).","journal-title":"Front. Immunol."},{"key":"356_CR195","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3389\/fimmu.2018.00984","volume":"9","author":"V Pistoia","year":"2018","unstructured":"Pistoia, V. et al. Human gammadelta T-cells: from surface receptors to the therapy of high-risk leukemias. Front. Immunol. 9, 984 (2018).","journal-title":"Front. Immunol."},{"key":"356_CR196","doi-asserted-by":"crossref","first-page":"578741","DOI":"10.1155\/2014\/578741","volume":"2014","author":"E R\u00e5destad","year":"2014","unstructured":"R\u00e5destad, E. et al. Alpha\/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors. J. Immunol. Res. 2014, 578741 (2014).","journal-title":"J. Immunol. Res."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-020-0356-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-020-0356-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-020-0356-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:43:50Z","timestamp":1684619030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-0356-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":196,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["356"],"URL":"https:\/\/doi.org\/10.1038\/s41571-020-0356-4","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"16 March 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.R.B. is a founder of Tmunity Therapeutics, and receives research support and is a member of the Scientific Advisory Board for BlueRock Therapeutics. G.R.H. has received research funding from Compass Therapeutics and Roche. W.J.M. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}